Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL8036967 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL466239 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL685473 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8099424 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL3676 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075366 | 0.99 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13449 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727527-A2 | GRP78 TARGETED LIPOSOMAL NANOPARTICLES (TLNPS) FOR THE TREATMENT OF CANCER | University of Notre Dame du Lac (US) | 2026-04-22 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250332274-A1 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | UNIV YALE (US) | 2025-10-30 | — | — | US | claimed |
| EP-3806898-B1 | GREMLIN-1 ANTAGONIST FOR USE IN THE TREATMENT OF CANCER | UCB Biopharma SRL (BE) | 2025-10-08 | — | — | EP | claimed |
| WO-2007130429-A2 | HISTONE DEACETYLASE AND TUBULIN DEACETYLASE INHIBITORS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070197473-A1 | Methods of using SAHA and Bortezomib for treating cancer | MERCK & CO., INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007056470-A2 | NEUROPILIN ANTAGONISTS | GENENTECH, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20060239909-A1 | Treatment of protein degradation disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-10-26 | — | — | US | claimed |
| WO-2006102557-A2 | TREATMENT OF PROTEIN DEGRADATION DISORDERS | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060079461-A1 | Treatment of multiple myeloma by inhibition of p38 MAP kinase | SCIOS, INC. (US) | 2006-04-13 | — | — | US | claimed |
| US-20060052390-A1 | Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition | SCIOS, INC. (US) | 2006-03-09 | — | — | US | claimed |
| EP-1581204-A1 | INHIBITION OF MELANOGENESIS AND MELANOMA METASTASIS WITH P-AMINOBENZOIC ACID (PABA) | NEW YORK UNIVERSITY (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040167222-A1 | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-26 | — | — | US | claimed |
| WO-2004058241-A1 | INHIBITION OF MELANOGENESIS AND MELANOMA METASTASIS WITH P-AMINOBENZOIC ACID (PABA) | NEW YORK UNIVERSITY (US) | 2004-07-15 | — | — | WO | claimed |